Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Mitul D. Gandhi, Andrew M. Evens, Timothy S. Fenske, Paul Hamlin, Bertrand Coiffier, Andreas Engert, Alison J. Moskowitz, Nilanjan Ghosh, Adam M. Petrich, Jon Lomasney, Amy Chadburn, Gary S. Wood, Katrin Salva, Beatrice Nardone, Steven M. Trifilio, Dennis W. Raisch, Dennis P. West, Leo I. Gordon, Jane N. Winter

Blood (2014) 123 (18): 2895–2897.

https://doi.org/10.1182/blood-2014-03-561878

Published: 2014

Journal Articles

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Mitul Gandhi, MD, Andrew M Evens, DO, MSc, Timothy S. Fenske, MD, Paul Hamlin, MD, Bertrand Coiffier, MD, PhD, Andreas Engert, MD, Alison J. Moskowitz, MD, Nilanjan Ghosh, MD, PhD, Adam M. Petrich, MD, Jon Lomasney, M.D., Amy Chadburn, M.D., Gary S. Wood, MD, Katrin Salva, M.D., Steven M Trifilio, BS Pharm, Dennis W. Raisch, PhD, MS, RPh, Dennis West, PhD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2013) 122 (21): 4380.

https://doi.org/10.1182/blood.V122.21.4380.4380

Published: 2013

Journal Articles

Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts

Blood (2011) 118 (21): 942.

https://doi.org/10.1182/blood.V118.21.942.942

Published: 2011

Journal Articles

Effectiveness of a Single 3 Mg Rasburicase Dose for the Management of Hyperuricemia in Patients with Hematologic Malignancies.

Steven M Trifilio, Judy Pi, Mary Golf, Katherine Coyle, Debbie Greenberg, Jennifer Zook, Diane Newman, Molly Koslowsky, Jayesh Mehta

Blood (2009) 114 (22): 2479.

https://doi.org/10.1182/blood.V114.22.2479.2479

Published: 2009

Journal Articles

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

Charles L Bennett, MD, PhD, Athena T Samaras, BA, June M McKoy, MD, JD, MPH, Beatrice J Edwards, MD, FACP, Mi Zheng, Matthew J Fisher, BA, Simone N Boyle, BA, Steven M Trifilio, RPh, Monica Boen, BA, Dianne Deleon, BA, Dennis P West, PhD

Blood (2009) 114 (22): 4538.

https://doi.org/10.1182/blood.V114.22.4538.4538

Published: 2009

Journal Articles

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

Charles L. Bennett, MD, PhD, Ari Polish, MD, Athena T Samaras, BA, Mi Zheng, Dennis P West, PhD, Steven M Trifilio, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Matthew J Fisher, June M McKoy, MD, JD, MPH

Blood (2009) 114 (22): 4555.

https://doi.org/10.1182/blood.V114.22.4555.4555

Published: 2009

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Charles L. Bennett, MD, PhD, MPP, Benjamin Kim, MD, Athena T Samaras, BA, Allen R Nissenson, MD, FACP, A. Oliver Sartor, MD, D. Mark Courtney, MD, Robert I. Liem, MD, Dennis P West, PhD, Simone N Boyle, BA, Robin L Wagner, Carolyn E Goldstein, Steven M Trifilio, RPh, David M Spiegel, MD, FACP, Stephen Y Lai, MD, PhD

Blood (2008) 112 (11): 4680.

https://doi.org/10.1182/blood.V112.11.4680.4680

Published: 2008

Journal Articles

A Multi-Institution Retrospective Case Report Analysis of Emergence of Breakthrough Zygomycoses in Patients on Prior Voriconazole Therapy.

Steven M. Trifilio, RPh, Lakshmi Balasubramanian, MD, MS, Jayesh Mehta, MD, Martin S. Tallman, MD, LeAnne Kennedy, PharmD, Charles L. Bennett, MD, MPP, Dimitrios P. Kontoyiannis, MD

Blood (2005) 106 (11): 3227.

https://doi.org/10.1182/blood.V106.11.3227.3227

Published: 2005

Journal Articles

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Blood (2005) 106 (10): 3343–3347.

https://doi.org/10.1182/blood-2005-02-0508

Published: 2005

Journal Articles

Severe Gemcitabine-Associated Lung Injury in Hodgkins Disease & Other Cancers: Reporting Quality and Clinical Characteristics of Cases Reported in the Medical Literature and to the FDA.

Steven M. Belknap, MD, Nicolas Slimack, BA, Timothy Kuzel, MD, Kenneth R. Carson, MD, Paul R. Yarnold, PhD, Dennis W. Raisch, PhD, Steven M. Trifilio, PharmD, Charles L. Bennett, MD

Blood (2004) 104 (11): 3145.

https://doi.org/10.1182/blood.V104.11.3145.3145

Published: 2004

NARROW

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts

Effectiveness of a Single 3 Mg Rasburicase Dose for the Management of Hyperuricemia in Patients with Hematologic Malignancies.

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

A Multi-Institution Retrospective Case Report Analysis of Emergence of Breakthrough Zygomycoses in Patients on Prior Voriconazole Therapy.

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Severe Gemcitabine-Associated Lung Injury in Hodgkins Disease & Other Cancers: Reporting Quality and Clinical Characteristics of Cases Reported in the Medical Literature and to the FDA.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only